Skip to main content
Top
Published in: CNS Drugs 12/2023

24-11-2023 | Ketamine | Commentary

Context is a Critical for Psychoactive Drug Effects

Author: Kyle T. Greenway

Published in: CNS Drugs | Issue 12/2023

Login to get access

Excerpt

Pouyan et al. recently reviewed more than two decades of human and animal studies on the effects of lysergic acid diethylamide (LSD) using the Positive Valence Systems of the Research Domain Criteria (RDoC) framework [1]. Their comprehensive review demonstrates how RDoC can be successfully applied to a diverse body of psychopharmacological literature to yield mechanistic insights—for instance, that LSD can alter reward processing systems to enhance reward responsiveness. An equally important additional finding of this work is that the authors’ efforts to examine how their results might have been influenced by extrapharmacological factors were stymied by major gaps in the reviewed literature. Despite multiple lines of evidence demonstrating that serotonergic psychedelic drug effects are strongly influenced by contextual factors [2], such variables remain poorly defined, rarely standardized, and inconsistently reported. …
Literature
1.
go back to reference Pouyan N, Younesi Sisi F, Kargar A, Scheidegger M, McIntyre R, Morrow J. The effects of lysergic acid diethylamide (LSD) on the positive valence systems: A Research Domain Criteria (RDoC)-informed systematic review. CNS Drugs. 2023;37:12. https://doi.org/10.1007/s40263-023-01044-1. Pouyan N, Younesi Sisi F, Kargar A, Scheidegger M, McIntyre R, Morrow J. The effects of lysergic acid diethylamide (LSD) on the positive valence systems: A Research Domain Criteria (RDoC)-informed systematic review. CNS Drugs. 2023;37:12. https://​doi.​org/​10.​1007/​s40263-023-01044-1.
2.
go back to reference Carhart-Harris RL, Roseman L, Haijen E, Erritzoe D, Watts R, Branchi I, et al. Psychedelics and the essential importance of context. J Psychopharmacol. 2018;32:725–31.CrossRefPubMed Carhart-Harris RL, Roseman L, Haijen E, Erritzoe D, Watts R, Branchi I, et al. Psychedelics and the essential importance of context. J Psychopharmacol. 2018;32:725–31.CrossRefPubMed
3.
go back to reference Kaelen M, Giribaldi B, Raine J, Evans L, Timmerman C, Rodriguez N, et al. The hidden therapist: evidence for a central role of music in psychedelic therapy. Psychopharmacology. 2018;235:505–19.CrossRefPubMedPubMedCentral Kaelen M, Giribaldi B, Raine J, Evans L, Timmerman C, Rodriguez N, et al. The hidden therapist: evidence for a central role of music in psychedelic therapy. Psychopharmacology. 2018;235:505–19.CrossRefPubMedPubMedCentral
5.
go back to reference Kaelen M, Barrett FS, Roseman L, Lorenz R, Family N, Bolstridge M, et al. LSD enhances the emotional response to music. Psychopharmacology. 2015;232:3607–14.CrossRefPubMed Kaelen M, Barrett FS, Roseman L, Lorenz R, Family N, Bolstridge M, et al. LSD enhances the emotional response to music. Psychopharmacology. 2015;232:3607–14.CrossRefPubMed
6.
go back to reference Barrett FS, Preller KH, Herdener M, Janata P, Vollenweider FX. Serotonin 2A receptor signaling underlies LSD-induced alteration of the neural response to dynamic changes in music. Cereb Cortex. 2018;28:3939–50.CrossRefPubMed Barrett FS, Preller KH, Herdener M, Janata P, Vollenweider FX. Serotonin 2A receptor signaling underlies LSD-induced alteration of the neural response to dynamic changes in music. Cereb Cortex. 2018;28:3939–50.CrossRefPubMed
10.
go back to reference Deshon HJ, Rinkel M, Solomon HC. Mental changes experimentally produced by L. S. D. (d-Lysergic acid diethylamide tartrate). Psych Q. 1952;26:33–53.CrossRef Deshon HJ, Rinkel M, Solomon HC. Mental changes experimentally produced by L. S. D. (d-Lysergic acid diethylamide tartrate). Psych Q. 1952;26:33–53.CrossRef
11.
go back to reference Roseman L, Haijen E, Idialu-Ikato K, Kaelen M, Watts R, Carhart-Harris R. Emotional breakthrough and psychedelics: validation of the emotional breakthrough inventory. J Psychopharmacol. 2019;33:1076–87.CrossRefPubMed Roseman L, Haijen E, Idialu-Ikato K, Kaelen M, Watts R, Carhart-Harris R. Emotional breakthrough and psychedelics: validation of the emotional breakthrough inventory. J Psychopharmacol. 2019;33:1076–87.CrossRefPubMed
12.
go back to reference Griffiths RR, Johnson MW, Richards WA, Richards BD, McCann U, Jesse R. Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects. Psychopharmacology. 2011;218:649–65.CrossRefPubMedPubMedCentral Griffiths RR, Johnson MW, Richards WA, Richards BD, McCann U, Jesse R. Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects. Psychopharmacology. 2011;218:649–65.CrossRefPubMedPubMedCentral
13.
go back to reference Hartogsohn I. Set and setting, psychedelics and the placebo response: an extra-pharmacological perspective on psychopharmacology. J Psychopharmacol. 2016;30:1259–67.CrossRefPubMed Hartogsohn I. Set and setting, psychedelics and the placebo response: an extra-pharmacological perspective on psychopharmacology. J Psychopharmacol. 2016;30:1259–67.CrossRefPubMed
14.
go back to reference Garel N, Drury J, Thibault Lévesque J, Goyette N, Lehmann A, Looper K, et al. The Montreal model: an integrative biomedical-psychedelic approach to ketamine for severe treatment-resistant depression. Front Psychiatry. 2023;14:1268832.CrossRefPubMedPubMedCentral Garel N, Drury J, Thibault Lévesque J, Goyette N, Lehmann A, Looper K, et al. The Montreal model: an integrative biomedical-psychedelic approach to ketamine for severe treatment-resistant depression. Front Psychiatry. 2023;14:1268832.CrossRefPubMedPubMedCentral
15.
go back to reference Bremner JD, Krystal JH, Putnam FW, Southwick SM, Marmar C, Charney DS, et al. Measurement of dissociative states with the Clinician-Administered Dissociative States Scale (CADSS). J Trauma Stress. 1998;11:125–36.CrossRefPubMed Bremner JD, Krystal JH, Putnam FW, Southwick SM, Marmar C, Charney DS, et al. Measurement of dissociative states with the Clinician-Administered Dissociative States Scale (CADSS). J Trauma Stress. 1998;11:125–36.CrossRefPubMed
16.
go back to reference van Schalkwyk GI, Wilkinson ST, Davidson L, Silverman WK, Sanacora G. Acute psychoactive effects of intravenous ketamine during treatment of mood disorders: analysis of the Clinician Administered Dissociative State Scale. J Affect Disord. 2018;227:11–6.CrossRefPubMed van Schalkwyk GI, Wilkinson ST, Davidson L, Silverman WK, Sanacora G. Acute psychoactive effects of intravenous ketamine during treatment of mood disorders: analysis of the Clinician Administered Dissociative State Scale. J Affect Disord. 2018;227:11–6.CrossRefPubMed
18.
go back to reference Dakwar E, Anerella C, Hart CL, Levin FR, Mathew SJ, Nunes EV. Therapeutic infusions of ketamine: do the psychoactive effects matter? Drug Alcohol Depend. 2014;136:153–7.CrossRefPubMedPubMedCentral Dakwar E, Anerella C, Hart CL, Levin FR, Mathew SJ, Nunes EV. Therapeutic infusions of ketamine: do the psychoactive effects matter? Drug Alcohol Depend. 2014;136:153–7.CrossRefPubMedPubMedCentral
19.
20.
go back to reference D’Souza DC, Perry E, MacDougall L, Ammerman Y, Cooper T, Wu Y, et al. The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacol. 2004;29:1558–72.CrossRef D’Souza DC, Perry E, MacDougall L, Ammerman Y, Cooper T, Wu Y, et al. The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacol. 2004;29:1558–72.CrossRef
21.
go back to reference van Heugten-Van der Kloet D, Giesbrecht T, van Wel J, Bosker WM, Kuypers KP, Theunissen EL, et al. MDMA, cannabis, and cocaine produce acute dissociative symptoms. Psychiatry Research. 2015;228:907–12. van Heugten-Van der Kloet D, Giesbrecht T, van Wel J, Bosker WM, Kuypers KP, Theunissen EL, et al. MDMA, cannabis, and cocaine produce acute dissociative symptoms. Psychiatry Research. 2015;228:907–12.
22.
go back to reference Sanches RF, De Lima OF, Dos Santos RG, Macedo LRH, Maia-de-Oliveira JP, Wichert-Ana L, et al. Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a SPECT study. J Clin Psychopharmacol. 2016;36:77–81.CrossRefPubMed Sanches RF, De Lima OF, Dos Santos RG, Macedo LRH, Maia-de-Oliveira JP, Wichert-Ana L, et al. Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a SPECT study. J Clin Psychopharmacol. 2016;36:77–81.CrossRefPubMed
23.
go back to reference Feduccia AA, Jerome L, Yazar-Klosinski B, Emerson A, Mithoefer MC, Doblin R. Breakthrough for trauma treatment: safety and efficacy of MDMA-assisted psychotherapy compared to paroxetine and sertraline. Front Psychiatry. 2019;10:650.CrossRefPubMedPubMedCentral Feduccia AA, Jerome L, Yazar-Klosinski B, Emerson A, Mithoefer MC, Doblin R. Breakthrough for trauma treatment: safety and efficacy of MDMA-assisted psychotherapy compared to paroxetine and sertraline. Front Psychiatry. 2019;10:650.CrossRefPubMedPubMedCentral
24.
go back to reference Holze F, Vizeli P, Müller F, Ley L, Duerig R, Varghese N, et al. Distinct acute effects of LSD, MDMA, and d-amphetamine in healthy subjects. Neuropsychopharmacology. 2019;45:462–71.CrossRefPubMedPubMedCentral Holze F, Vizeli P, Müller F, Ley L, Duerig R, Varghese N, et al. Distinct acute effects of LSD, MDMA, and d-amphetamine in healthy subjects. Neuropsychopharmacology. 2019;45:462–71.CrossRefPubMedPubMedCentral
25.
go back to reference Thompson MR, Callaghan PD, Hunt GE, Cornish JL, McGregor IS. A role for oxytocin and 5-HT1A receptors in the prosocial effects of 3,4 methylenedioxymethamphetamine (“ecstasy”). Neuroscience. 2007;146:509–14.CrossRefPubMed Thompson MR, Callaghan PD, Hunt GE, Cornish JL, McGregor IS. A role for oxytocin and 5-HT1A receptors in the prosocial effects of 3,4 methylenedioxymethamphetamine (“ecstasy”). Neuroscience. 2007;146:509–14.CrossRefPubMed
26.
go back to reference Edsinger E, Dölen G. A conserved role for serotonergic neurotransmission in mediating social behavior in octopus. Curr Biol. 2018;28:3136-3142.e4.CrossRefPubMed Edsinger E, Dölen G. A conserved role for serotonergic neurotransmission in mediating social behavior in octopus. Curr Biol. 2018;28:3136-3142.e4.CrossRefPubMed
27.
go back to reference Molla H, Lee R, Lyubomirsky S, de Wit H. Drug-induced social connection: both MDMA and methamphetamine increase feelings of connectedness during controlled dyadic conversations. Sci Rep. 2023;13:15846.CrossRefPubMedPubMedCentral Molla H, Lee R, Lyubomirsky S, de Wit H. Drug-induced social connection: both MDMA and methamphetamine increase feelings of connectedness during controlled dyadic conversations. Sci Rep. 2023;13:15846.CrossRefPubMedPubMedCentral
28.
go back to reference Seiden LS, Sabol KE, Ricaurte GA. Amphetamine: effects on catecholamine systems and behavior. Annu Rev Pharmacol Toxicol. 1993;33:639–76.CrossRefPubMed Seiden LS, Sabol KE, Ricaurte GA. Amphetamine: effects on catecholamine systems and behavior. Annu Rev Pharmacol Toxicol. 1993;33:639–76.CrossRefPubMed
29.
go back to reference Bedi G, Hyman D, de Wit H. Is ecstasy an “empathogen”? effects of ±3,4-methylenedioxymethamphetamine on prosocial feelings and identification of emotional states in others. Biol Psychiat. 2010;68:1134–40.CrossRefPubMed Bedi G, Hyman D, de Wit H. Is ecstasy an “empathogen”? effects of ±3,4-methylenedioxymethamphetamine on prosocial feelings and identification of emotional states in others. Biol Psychiat. 2010;68:1134–40.CrossRefPubMed
30.
go back to reference Corbin WR, Hartman JD, Bruening AB, Fromme K. Contextual influences on subjective alcohol response. Exp Clin Psychopharmacol. 2021;29:48–58.CrossRefPubMed Corbin WR, Hartman JD, Bruening AB, Fromme K. Contextual influences on subjective alcohol response. Exp Clin Psychopharmacol. 2021;29:48–58.CrossRefPubMed
31.
go back to reference Alboni S, van Dijk RM, Poggini S, Milior G, Perrotta M, Drenth T, et al. Fluoxetine effects on molecular, cellular and behavioral endophenotypes of depression are driven by the living environment. Mol Psychiatry. 2017;22:552–61.CrossRefPubMed Alboni S, van Dijk RM, Poggini S, Milior G, Perrotta M, Drenth T, et al. Fluoxetine effects on molecular, cellular and behavioral endophenotypes of depression are driven by the living environment. Mol Psychiatry. 2017;22:552–61.CrossRefPubMed
32.
go back to reference Gerevich J, Bácskai E, Farkas L, Danics Z. A case report: pavlovian conditioning as a risk factor of heroin “overdose” death. Harm Reduct J. 2005;2:11.CrossRefPubMedPubMedCentral Gerevich J, Bácskai E, Farkas L, Danics Z. A case report: pavlovian conditioning as a risk factor of heroin “overdose” death. Harm Reduct J. 2005;2:11.CrossRefPubMedPubMedCentral
33.
go back to reference Siegel S. The heroin overdose mystery. Curr Dir Psychol Sci. 2016;25:375–9.CrossRef Siegel S. The heroin overdose mystery. Curr Dir Psychol Sci. 2016;25:375–9.CrossRef
34.
go back to reference O’Brien CP, Childress AR, McLellan AT, Ehrman R. A learning model of addiction. Res Publ Assoc Res Nerv Ment Dis. 1992;70:157–77.PubMed O’Brien CP, Childress AR, McLellan AT, Ehrman R. A learning model of addiction. Res Publ Assoc Res Nerv Ment Dis. 1992;70:157–77.PubMed
35.
go back to reference Pouyan N, Halvaei Khankahdani Z, Younesi Sisi F, Lee Y, Rosenblat JD, Teopiz KM, et al. A Research Domain Criteria (RDoC)-guided dashboard to review psilocybin target domains: a systematic review. CNS Drugs. 2022;36:1031–47.CrossRefPubMedPubMedCentral Pouyan N, Halvaei Khankahdani Z, Younesi Sisi F, Lee Y, Rosenblat JD, Teopiz KM, et al. A Research Domain Criteria (RDoC)-guided dashboard to review psilocybin target domains: a systematic review. CNS Drugs. 2022;36:1031–47.CrossRefPubMedPubMedCentral
36.
go back to reference Hartogsohn I. American trip: set, setting, and the psychedelic experience in the twentieth century. New York: MIT Press; 2020.CrossRef Hartogsohn I. American trip: set, setting, and the psychedelic experience in the twentieth century. New York: MIT Press; 2020.CrossRef
37.
go back to reference Carhart-Harris RL, Bolstridge M, Rucker J, Day CMJ, Erritzoe D, Kaelen M, et al. Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. The Lancet Psychiatry. 2016;3:619–27.CrossRefPubMed Carhart-Harris RL, Bolstridge M, Rucker J, Day CMJ, Erritzoe D, Kaelen M, et al. Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. The Lancet Psychiatry. 2016;3:619–27.CrossRefPubMed
38.
go back to reference Butcher NJ, Monsour A, Mew EJ, Chan A-W, Moher D, Mayo-Wilson E, et al. Guidelines for reporting outcomes in trial reports: the CONSORT-outcomes 2022 extension. JAMA. 2022;328:2252–64.CrossRefPubMed Butcher NJ, Monsour A, Mew EJ, Chan A-W, Moher D, Mayo-Wilson E, et al. Guidelines for reporting outcomes in trial reports: the CONSORT-outcomes 2022 extension. JAMA. 2022;328:2252–64.CrossRefPubMed
39.
go back to reference Hoffmann TC, Glasziou PP, Boutron I, Milne R, Perera R, Moher D, et al. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. BMJ. 2014;348: g1687.CrossRefPubMed Hoffmann TC, Glasziou PP, Boutron I, Milne R, Perera R, Moher D, et al. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. BMJ. 2014;348: g1687.CrossRefPubMed
40.
go back to reference Aday JS, Heifets BD, Pratscher SD, Bradley E, Rosen R, Woolley JD. Great Expectations: recommendations for improving the methodological rigor of psychedelic clinical trials. Psychopharmacology. 2022;239:1989–2010.CrossRefPubMedPubMedCentral Aday JS, Heifets BD, Pratscher SD, Bradley E, Rosen R, Woolley JD. Great Expectations: recommendations for improving the methodological rigor of psychedelic clinical trials. Psychopharmacology. 2022;239:1989–2010.CrossRefPubMedPubMedCentral
41.
go back to reference Hakak-Zargar B, Tamrakar A, Voth T, Sheikhi A, Multani J, Schütz CG. The utility of research domain criteria in diagnosis and management of dual disorders: a mini-review. Front Psych. 2022;13: 805163.CrossRef Hakak-Zargar B, Tamrakar A, Voth T, Sheikhi A, Multani J, Schütz CG. The utility of research domain criteria in diagnosis and management of dual disorders: a mini-review. Front Psych. 2022;13: 805163.CrossRef
Metadata
Title
Context is a Critical for Psychoactive Drug Effects
Author
Kyle T. Greenway
Publication date
24-11-2023
Publisher
Springer International Publishing
Keyword
Ketamine
Published in
CNS Drugs / Issue 12/2023
Print ISSN: 1172-7047
Electronic ISSN: 1179-1934
DOI
https://doi.org/10.1007/s40263-023-01053-0

Other articles of this Issue 12/2023

CNS Drugs 12/2023 Go to the issue

Acknowledgement to Referees

Acknowledgement to Referees